Stereoselective Binding of 11C-raclopride in Living Human Brain--a Search for Extrastriatal Central D2-dopamine Receptors by PET

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1988 Jan 1

PMID 3131792

Citations 53

Authors

L Farde

S Pauli

H Hall

L Eriksson

C Halldin

T Hogberg

L Nilsson

I Sjogren

S Stone-Elander

Affiliations

Soon will be listed here.

Abstract

The selective D2-dopamine receptor antagonist raclopride and its pharmacologically inactive (R)-enantiomer FLB472 were labelled with 11C and used in a study with positron emission tomography to examine the stereoselectivity of 11C-raclopride binding to central D2-dopamine receptors in three healthy men. After the injection of 11C-raclopride, there was a high accumulation of radioactivity in the dopamine-rich basal ganglia, whereas after the injection of 11C-FLB472 there was no such accumulation of radioactivity. Thus, the binding of 11C-raclopride is stereoselective. Distribution ratios [radioactivity in a brain region/"free" (not protein-bound) radioactivity in plasma] were calculated for the two enantiomers to study regional differences in the accumulation of radioactivity. The distribution ratios in white matter were similar for the two enantiomers. In the putamen, a three to four-fold higher distribution ratio was found for 11C-raclopride than for 11C-FLB472, reflecting the presence of specific binding of 11C-raclopride binding to D2-dopamine receptors in the basal ganglia. In the temporal and frontal cortices the distribution ratios were, however, only a few per cent higher for 11C-raclopride than for 11C-FLB472, indicating that if D2-dopamine receptors are present in the human neocortex, then their density is indeed very low.

Citing Articles

Papenberg G, Karalija N, Salami A, Johansson J, Wahlin A, Andersson M Cereb Cortex. 2025; 35(2).

PMID: 39756432 PMC: 11795306. DOI: 10.1093/cercor/bhae481.

Amphetamine-induced dopamine release in rat: Whole-brain spatiotemporal analysis with [C]raclopride and positron emission tomography.

Johansson J, Ericsson M, Axelsson J, Af Bjerken S, Virel A, Karalija N J Cereb Blood Flow Metab. 2023; 44(3):434-445.

PMID: 37882727 PMC: 10870964. DOI: 10.1177/0271678X231210128.

Longitudinal Dopamine D2 Receptor Changes and Cerebrovascular Health in Aging.

Karalija N, Johansson J, Papenberg G, Wahlin A, Salami A, Kohncke Y Neurology. 2022; 99(12):e1278-e1289.

PMID: 35790424 PMC: 9576296. DOI: 10.1212/WNL.0000000000200891.

All-Atom Molecular Dynamics Investigations on the Interactions between D2 Subunit Dopamine Receptors and Three C-Labeled Radiopharmaceutical Ligands.

Moldovean S, Timaru D, Chis V Int J Mol Sci. 2022; 23(4).

PMID: 35216115 PMC: 8880249. DOI: 10.3390/ijms23042005.

Fronto-striatal dopamine D2 receptor availability is associated with cognitive variability in older individuals with low dopamine integrity.

Korkki S, Papenberg G, Karalija N, Garrett D, Riklund K, Lovden M Sci Rep. 2021; 11(1):21089.

PMID: 34702857 PMC: 8548594. DOI: 10.1038/s41598-021-00106-y.

References

Mazziotta J, Phelps M, Plummer D, Kuhl D . Quantitation in positron emission computed tomography: 5. Physical--anatomical effects. J Comput Assist Tomogr. 1981; 5(5):734-43. DOI: 10.1097/00004728-198110000-00029. View

Kohler C, Radesater A . Autoradiographic visualization of dopamine D-2 receptors in the monkey brain using the selective benzamide drug [3H]raclopride. Neurosci Lett. 1986; 66(1):85-90. DOI: 10.1016/0304-3940(86)90170-9. View

Giacomini J, Nelson W, Theodore L, Wong F, Rood D, Giacomini K . The pharmacokinetics and pharmacodynamics of d- and dl-verapamil in rabbits. J Cardiovasc Pharmacol. 1985; 7(3):469-75. DOI: 10.1097/00005344-198505000-00009. View

Thijssen H, Baars L . Stereoselective aspects in the pharmacokinetics and pharmacodynamics of acenocoumarol and its amino and acetamido derivatives in the rat. Drug Metab Dispos. 1985; 13(5):593-7. View

Olanoff L, Walle T, Walle U, Cowart T, Gaffney T . Stereoselective clearance and distribution of intravenous propranolol. Clin Pharmacol Ther. 1984; 35(6):755-61. DOI: 10.1038/clpt.1984.107. View

Litton J, Bergstrom M, Eriksson L, Bohm C, Blomqvist G, Kesselberg M . Performance study of the PC-384 positron camera system for emission tomography of the brain. J Comput Assist Tomogr. 1984; 8(1):74-87. DOI: 10.1097/00004728-198402000-00016. View

Creese I, Burt D, Snyder S . Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976; 192(4238):481-3. DOI: 10.1126/science.3854. View

Wagner Jr H, Burns H, Dannals R, Wong D, Langstrom B, Duelfer T . Imaging dopamine receptors in the human brain by positron tomography. Science. 1983; 221(4617):1264-6. DOI: 10.1126/science.6604315. View

Sedvall G, Farde L, Persson A, Wiesel F . Imaging of neurotransmitter receptors in the living human brain. Arch Gen Psychiatry. 1986; 43(10):995-1005. DOI: 10.1001/archpsyc.1986.01800100089012. View

10.

Farde L, Wiesel F, Jansson P, Uppfeldt G, WAHLEN A, Sedvall G . An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. Psychopharmacology (Berl). 1988; 94(1):1-7. DOI: 10.1007/BF00735871. View

11.

Bergstrom M, Boethius J, Eriksson L, Greitz T, Ribbe T, WIDEN L . Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. J Comput Assist Tomogr. 1981; 5(1):136-41. DOI: 10.1097/00004728-198102000-00027. View

12.

Farde L, Hall H, Ehrin E, Sedvall G . Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science. 1986; 231(4735):258-61. DOI: 10.1126/science.2867601. View

13.

Hall H, Farde L, Sedvall G . Human dopamine receptor subtypes--in vitro binding analysis using 3H-SCH 23390 and 3H-raclopride. J Neural Transm. 1988; 73(1):7-21. DOI: 10.1007/BF01244618. View

14.

Seeman P, Lee T, Wong K . Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976; 261(5562):717-9. DOI: 10.1038/261717a0. View

15.

Bannon M, Roth R . Pharmacology of mesocortical dopamine neurons. Pharmacol Rev. 1983; 35(1):53-68. View

16.

Martres M, Bouthenet M, Sales N, Sokoloff P, Schwartz J . Widespread distribution of brain dopamine receptors evidenced with [125I]iodosulpride, a highly selective ligand. Science. 1985; 228(4700):752-5. DOI: 10.1126/science.3838821. View

17.

Kohler C, Hall H, Ogren S, Gawell L . Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol. 1985; 34(13):2251-9. DOI: 10.1016/0006-2952(85)90778-6. View

18.

De Keyser J, De Backer J, Ebinger G, Vauquelin G . Regional distribution of the dopamine D2 receptors in the mesotelencephalic dopamine neuron system of human brain. J Neurol Sci. 1985; 71(1):119-27. DOI: 10.1016/0022-510x(85)90041-3. View

19.

Smith D . Stereopsychopharmacology: past, present and future. Prog Neuropsychopharmacol Biol Psychiatry. 1984; 8(3):327-50. View

20.

Carlsson A, Lindqvist M . EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. Acta Pharmacol Toxicol (Copenh). 1963; 20:140-4. DOI: 10.1111/j.1600-0773.1963.tb01730.x. View